Literature DB >> 17174219

Anticoagulants and their reversal.

Sam Schulman1, Nick R Bijsterveld.   

Abstract

In an exciting era with many alternatives to the old anticoagulants heparin and warfarin emerging on the scene, awareness of the possibility to reverse their effect is mandatory. In this review, the traditional antidotes for warfarin (vitamin K, plasma, and prothrombin complex concentrate) and for heparin (protamine) are described together with the newer alternatives (recombinant activated factor VII, concatameric peptides, and recombinant platelet factor 4). For some of the newer anticoagulants, possible antidotes have been identified, whereas other alternatives have been discarded. There is a very limited experience of deamino-d-arginine vasopressin or a von Willebrand factor VIII concentrate to counteract hirudin. The small direct thrombin inhibitors may be reversed with activated prothrombin complex concentrate but not with recombinant activated factor VII, whereas the latter agent appears to be effective against the pentasaccharides and the recombinant nematode anticoagulant protein C2. Additional options that may become available in the future are also discussed briefly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17174219     DOI: 10.1016/j.tmrv.2006.08.002

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  42 in total

Review 1.  Prothrombin complex concentrates: an update.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Authors:  Andrew J Gale; Darlene J Elias; Patricia M Averell; Paul S Teirstein; Mitchell Buck; Steven D Brown; Zinaida Polonskaya; Andrew K Udit; M G Finn
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

Review 3.  Proteomics: applications in transfusion medicine.

Authors:  Giancarlo Maria Liumbruno
Journal:  Blood Transfus       Date:  2008-04       Impact factor: 3.443

Review 4.  Clinical use and the Italian demand for prothrombin complex concentrates.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Monica Lanzoni; Fabio Candura; Stefania Vaglio; Samantha Profili; Giuseppina Facco; Gabriele Calizzani; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

5.  Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Authors:  Secgin Soyuncu; Savas Aslan; Halil Mutlu; Firat Bektas
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

Review 7.  New oral anticoagulants in non-valvular atrial fibrillation.

Authors:  Pietro Francia; Carmen Adduci; Daria Santini; Beatrice Musumeci; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-05-08

8.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

9.  Polyphosphate as a general procoagulant agent.

Authors:  S A Smith; J H Morrissey
Journal:  J Thromb Haemost       Date:  2008-07-28       Impact factor: 5.824

Review 10.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.